Core Viewpoint - Yunnan Watson Bio-Technology Co., Ltd. has signed an amendment to the exclusive sublicense agreement with Notitia Biotechnologies Company to expand its development and commercialization rights in the field of gut microbiota health targeting non-patient populations, aligning with national health strategies [1][2]. Group 1: Agreement Details - The amendment allows Watson Bio to exclusively develop, manufacture, and commercialize core microbiota analysis, targeted transplantation, and nutritional formula technologies in mainland China, Hong Kong, and Macau for non-patient populations [1][2]. - The agreement aims to establish a dual-track layout of "disease treatment intervention" and "chronic disease prevention + health nutrition," providing comprehensive health solutions [1][2]. - The amendment does not constitute a related party transaction or a major asset restructuring as defined by regulations [1][2]. Group 2: Financial Terms - Watson Bio will pay Notitia a total of $1,500,000 in license issue fees, with specific payment schedules outlined [3][4]. - Ongoing royalties will be 6.5% of net sales from sublicensed products, with minimum royalty payments established for subsequent years [4][5]. - Milestone payments are structured based on the achievement of specific regulatory approvals and sales targets, with amounts ranging from $500,000 to $30,500,000 [5][6]. Group 3: Company Impact - The signing of the amendment is not expected to significantly impact the company's operating performance for the current year, as the financial arrangements are closely tied to product development progress [6]. - The payment structure is designed to ensure efficient use of funds and alleviate short-term financial burdens on the company [6].

格隆汇7月30日丨沃森生物(300142.SZ)公布，为深入贯彻国家"未病先防"慢病防控战略，进一步拓展"核 心菌群疗法"在精准微生态健康和功能性营养干预领域的研发及商业化应用，增强公司市场竞争力，董 事会同意公司与美国NotitiaBiotechnologies Company(以下简称"Notitia")签署《Amendment to ExclusiveSublicense Agreement》(《独家再许可协议之修正案》，以下简称"修正案")。根据修正案， Notitia将其与美国新泽西州立罗格斯大学签署的上游许可协议所获得的核心菌群分析、菌群靶向移植及 营养配方技术授予公司在中国大陆、香港和澳门地区针对非患者人群进行独占开发、制造及商业化的权 利。结合既有患者市场授权，本次修正案的签署标志着公司将实现"疾病治疗干预"与"慢病防治+大健康 营养"双轨布局，建立覆盖院内治疗、院外管理及多场景干预的综合性健康解决方案。此举紧密契合国 家非药物干预、强化慢病营养及慢病防控关口前移政策，通过整合现有临床路径及底层技术平台建设， 以更多元化产品形态覆盖亚健康及慢病高风险人群，为国家慢病综合防控体系提供新路径。 ...